<DOC>
	<DOCNO>NCT00803556</DOCNO>
	<brief_summary>To determine Maximally Tolerable Dose ( MTD ) KOS-1022 administered weekly combination trastuzumab combination trastuzumab paclitaxel patient advance solid tumor malignancy</brief_summary>
	<brief_title>Clinical Trial Combination Intravenous Alvespimycin ( KOS-1022 ) , Trastuzumab With Without Paclitaxel Patients With Advanced Solid Tumor Malignancies Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>KPS performance status &gt; = 70 % Schedule A : patient must histologically confirm solid tumor malignancy . Schedule B : patient must metastatic breast cancer Her2 amplification FISH 3+ Her2 overexpression immunohistochemistry ( `` IHC '' ) . Patients require measurable disease investigation . Disease must assess within 28 day prior treatment initiation All Adverse Events prior chemotherapy , surgery , radiotherapy , must resolve NCI CTCAE ( v. 3.0 ) Grade &lt; = 2 ( except alopecia ) The following laboratory result , within 10 day KOS1022 administration : Hemoglobin &gt; = 8.5 g/dL Absolute neutrophils count &gt; = 1.5 x 10*9* /L Platelet count &gt; = 75 x 10*9*/L Serum bilirubin &lt; = 2 x ULN AST ALT &lt; = 2.5 x ULN Serum creatinine &lt; = 2 x ULN Documented hypersensitivity reaction CTCAE Grade &gt; = 3 prior therapy contain trastuzumab Pregnant breastfeeding woman . Male patient must surgically sterile agree use acceptable method contraception Known active CNS metastases Administration chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) within 14 day prior receipt study medication . Patients 6 week last dose nitrosourea Patients Grade 2 high dyspnea rest room air ; patient clinically significant pulmonary comorbidity ( ) might predispose patient pulmonary toxicity Moderately severe dry eye Prior pulmonary toxic chemotherapy ( e.g , bleomycin carmustine ) Congestive heart failure , leave ventricular ejection fraction ( LVEF ) Any medical condition , Investigator 's opinion , would impose excessive risk patient Patients previous malignancy unless free recurrence least 5 year except cure basal cell carcinoma skin , carcinomainsitu either uterine cervix urinary bladder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>